Search
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, b...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2C8 InducersHydroxyprogesterone
go.drugbank.com/drugs/DB14570InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEslicarbazepine
go.drugbank.com/drugs/DB14575ApprovedEslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 InhibitorsPrednisolone hemisuccinate
go.drugbank.com/drugs/DB14633InvestigationalCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersFluprednidene acetate
go.drugbank.com/drugs/DB14634InvestigationalFluprednidene acetate is a corticosteroid. It has anti-inflammatory and anti-allergic properties.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersCannabinol
go.drugbank.com/drugs/DB14737InvestigationalCannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2A6 InhibitorsNarlaprevir
go.drugbank.com/drugs/DB14760InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalEtrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and S1P3 receptors. S1P receptors are membrane-derived lysophospholipid sig...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesAZD-1656
go.drugbank.com/drugs/DB14810InvestigationalAZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates